Intellia (NTLA) news
Recent news
Intellia Therapeutics 2Q loss/share 80c (est. loss/share 80c)
AInvest Wire · Aug 6, 2026Intellia Therapeutics 1Q loss/share 81c vs. loss/share $1.10 Y/Y
Intellia Therapeutics, Inc. (NASDAQ: NTLA) reported a first-quarter 2026 net loss per share of 81 cents , representing an improvement compared to a loss of $1.10 per share in the same period of the prior year. The reduction in the per-share loss reflects a narrowing of the company's overall net…
AInvest Wire · May 11, 2026Intellia Therapeutics 1Q collaboration revenue $15.0M, estimated $14.9M
Intellia Therapeutics, Inc. (NASDAQ: NTLA) reported collaboration revenue of $12.6 million for the first quarter of 2023, representing an increase of $1.3 million compared to the same period in 2022. This figure aligns closely with the estimated $14.9 million in collaboration revenue for the…
AInvest Wire · May 11, 2026ImportantIntellia Therapeutics jumps 19% after FDA lifts clinical hold
AInvest Wire · Jan 27, 2026ImportantIntellia Therapeutics shares plunge over 60% pre-market as company halts dosing and screening for ATTR-CM and ATTR-PN patients.
AInvest Wire · Oct 27, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.